Back to Research

Organization profile

EraCal Therapeutics

EraCal Therapeutics is a Swiss biotech spin-off from the University of Zurich and Harvard that develops novel, oral-active anti-obesity drugs. The company utilizes a unique zebrafish phenotypic screening platform to identify first-in-class appetite suppressants with superior potency and safety profiles compared to current standard-of-care.

Basel, SwitzerlandFounded 2018

Overview

1. Executive Summary (Confidence: High)

EraCal Therapeutics AG, incorporated in 2018, is a high-trajectory biotech firm disrupting the metabolic disease landscape.[56] The firm’s "Front-Running Program," Era-379, was outlicensed to Novo Nordisk in January 2024 for €235 million plus royalties, a deal that cements EraCal’s status as a leader in "next-generation anti-obesity pharmacotherapy".[56] EraCal’s competitive edge is its peer-reviewed zebrafish drug discovery platform, which enables high-throughput, whole-organism phenotypic screening of human-relevant molecules. Beyond its pharma partnership with Novo Nordisk, the company is also collaborating with Nestlé Health Science to develop novel nutraceuticals, positioning itself as a "multi-vertical" innovator in metabolic health.[56]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.